Anebulo Pharmaceuticals to Delist from Nasdaq and Deregister with SEC.

Anebulo Pharmaceuticals intends to voluntarily delist from Nasdaq and deregister with the SEC to terminate and suspend its reporting obligations under the Exchange Act. The Company's board of directors approved the decision to delist and deregister. Anebulo is a clinical-stage pharmaceutical company developing solutions for acute cannabis-induced toxic effects.